Novo Nordisk (NVO)
(Delayed Data from NYSE)
$48.19 USD
+1.12 (2.38%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $48.34 +0.15 (0.31%) 7:58 PM ET
4-Sell of 5 4
B Value C Growth B Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NVO 48.19 +1.12(2.38%)
Will NVO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NVO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NVO
Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q2 Earnings
Novo Nordisk (NVO) Registers a Bigger Fall Than the Market: Important Facts to Note
NVO: What are Zacks experts saying now?
Zacks Private Portfolio Services
NVO Stock Crashes 22% After 2025 View Cut: More Downside Ahead?
The Zacks Analyst Blog Highlights Tempus AI, NVIDIA, AstraZeneca and Novo Nordisk
Tempus AI or NVIDIA: Which is the Smarter Bet in AI-Backed Healthcare?
Other News for NVO
Trending stocks this week: Wall Street stumbles, Big Tech shines, and Figma steals the show
Notable analyst calls this week: Nike, Microsoft and Sarepta among top picks
Benzinga Bulls And Bears: Celestica, Carvana, Novo Nordisk — And Fed Holds Rates Despite Trump Pressure
Market Voices: Trump vs. Big Pharma, Swiss tariffs, tariff legality
Trump Administration Plan Signals Shift Toward Weight-Loss Drug Coverage For Medicare Patients